A phase II trial of sorafenib in patients with metastatic neuroendocrine tumors (NET): a phase II consortium (P2C) study.

Authors
Category Primary study
JournalProceedings, annual meeting of the American Society of Clinical Oncology
Year 2007
This article has no abstract
Epistemonikos ID: 13bf7018fa027f7c9ffc3e4b0f431eeb8c879bb1
First added on: Jun 25, 2020